- Szerzők: Marine Maurel, Esther Kissling, Francisco Pozo, Silke Buda, Gergő Túri, Beatrix Oroszi, Iván Martínez-Baz, HR1, Neus Latorre-Margalef et al
- Megjelenés: 2024, Influenza and other respiratory viruses
- URL: https://onlinelibrary.wiley.com/doi/10.1111/irv.70009
- MTMT azonosító: 35540716
Absztrakt: We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case–control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: −11–48) and 5% (95% CI: −92–56) among those with symptom onset 1–5, 6–11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.